Infographics 
Overview
SCIENTIFIC SCORE
Moderately Effective
Based on 9 Researches
8.4
USERS' SCORE
Good
Based on 3 Reviews
8.3
Supplement Facts
Serving Size: 1 tbsp (15 ml)
Amount Per Serving
%DV
Calories
120
Total Fat
14 g
18%
Saturated Fat
2.5 g
13%
Polyunsaturated Fat
8 g
Monounsaturated Fat
2 g
Sodium
0 mg
0%
Total Carbohydrate
0 g
0%
Protein
0 g
Vitamin E
20 mg
130%
Top Medical Research Studies
9
In our exploration of how certain natural compounds can impact rheumatoid arthritis (RA), we focused on the total flavonoids derived from Schltr., specifically identifying the effects of quercetin. Our research employed various methods, including cellular and animal models, to examine how these compounds inhibit TNF-α, a key player in inflammation and joint deterioration.
We discovered that quercetin stands out among several compounds, demonstrating a strong ability to reduce TNF-α activity. This reduction corresponds with decreased cellular injury and apoptosis in our models, showcasing quercetin's potential as a protective agent against RA symptoms. Through advanced techniques such as molecular docking and thermal profiling, we verified that quercetin binds to TNF-α, eventually diminishing the inflammatory processes related to arthritis.
The findings suggest that quercetin plays a significant role in suppressing the TNF-α/NF-κB signaling pathway, which is crucial in the development of RA. By blocking certain inflammatory responses, quercetin appears to mitigate pain and joint damage, positioning it as a hopeful candidate for RA treatment. Overall, our investigation highlights quercetin's promising properties as a natural anti-inflammatory agent for those suffering from arthritis.
We discovered that quercetin stands out among several compounds, demonstrating a strong ability to reduce TNF-α activity. This reduction corresponds with decreased cellular injury and apoptosis in our models, showcasing quercetin's potential as a protective agent against RA symptoms. Through advanced techniques such as molecular docking and thermal profiling, we verified that quercetin binds to TNF-α, eventually diminishing the inflammatory processes related to arthritis.
The findings suggest that quercetin plays a significant role in suppressing the TNF-α/NF-κB signaling pathway, which is crucial in the development of RA. By blocking certain inflammatory responses, quercetin appears to mitigate pain and joint damage, positioning it as a hopeful candidate for RA treatment. Overall, our investigation highlights quercetin's promising properties as a natural anti-inflammatory agent for those suffering from arthritis.
Read More
9
We set out to investigate whether proteins from the Clonorchis sinensis parasite could help reduce inflammation in rheumatoid arthritis (RA) and ankylosing spondylitis (AS). Our research involved analyzing blood samples from healthy individuals, as well as patients with these conditions, to assess how these proteins affected immune cells.
Through our experiments, we discovered that treatment with Clonorchis sinensis excretory/secretory proteins (CS-ESP) didn’t harm the health of the blood cells. In fact, these proteins significantly decreased the levels of certain inflammatory markers like IL-17A and GM-CSF that are associated with these types of arthritis.
We also tested these proteins in a mouse model of arthritis and found that CS-ESP notably alleviated symptoms like pain and swelling. Moreover, we isolated specific proteins, Cs-GT and Cs-Severin, which showed similar anti-inflammatory properties without affecting cell viability.
Overall, our findings suggest that these proteins may hold promise as new treatments to improve the signs and symptoms of arthritis. This study opens the door to further research on how such proteins can be used in therapeutic applications for arthritis patients.
Through our experiments, we discovered that treatment with Clonorchis sinensis excretory/secretory proteins (CS-ESP) didn’t harm the health of the blood cells. In fact, these proteins significantly decreased the levels of certain inflammatory markers like IL-17A and GM-CSF that are associated with these types of arthritis.
We also tested these proteins in a mouse model of arthritis and found that CS-ESP notably alleviated symptoms like pain and swelling. Moreover, we isolated specific proteins, Cs-GT and Cs-Severin, which showed similar anti-inflammatory properties without affecting cell viability.
Overall, our findings suggest that these proteins may hold promise as new treatments to improve the signs and symptoms of arthritis. This study opens the door to further research on how such proteins can be used in therapeutic applications for arthritis patients.
Read More
9
We explored the role of stromal cell-derived factor 1 (SDF-1) in alleviating osteoarthritis (OA), the most prevalent joint disease affecting millions. Our research delved into how SDF-1 could mitigate the progression of OA symptoms, focusing specifically on its impact on mitochondrial dysfunction within cartilage cells.
Using both OA chondrocytes and a collagen-induced osteoarthritis (CIOA) mouse model, we treated these cells and animals with SDF-1. We then assessed various markers related to mitochondrial function and cartilage health. Interestingly, we discovered that levels of important proteins like SOD2 and PGC-1α were lower in OA affected cells and tissues. Treatment with SDF-1 notably corrected these deficits, suggesting a promising pathway for restoring mitochondrial health and, consequently, improving OA symptoms.
Notably, when we inhibited Sirt3—an enzyme linked to mitochondrial function—prior to SDF-1 treatment, the benefits were diminished. This suggests that the Sirt3/PGC-1α signaling pathway is critical for the therapeutic effect of SDF-1 in OA. Thus, our findings indicate that SDF-1 stands out as a potential new treatment for OA, offering hope beyond traditional symptom management strategies.
Using both OA chondrocytes and a collagen-induced osteoarthritis (CIOA) mouse model, we treated these cells and animals with SDF-1. We then assessed various markers related to mitochondrial function and cartilage health. Interestingly, we discovered that levels of important proteins like SOD2 and PGC-1α were lower in OA affected cells and tissues. Treatment with SDF-1 notably corrected these deficits, suggesting a promising pathway for restoring mitochondrial health and, consequently, improving OA symptoms.
Notably, when we inhibited Sirt3—an enzyme linked to mitochondrial function—prior to SDF-1 treatment, the benefits were diminished. This suggests that the Sirt3/PGC-1α signaling pathway is critical for the therapeutic effect of SDF-1 in OA. Thus, our findings indicate that SDF-1 stands out as a potential new treatment for OA, offering hope beyond traditional symptom management strategies.
Read More
Most Useful Reviews
9
Great help
Wonderful. Simply a great, pure product that we are using for arthritis, and it has proven to be very helpful for my husband's bad back. I love that it's entirely natural.
Read More
7.5
Strength and mobility
12 people found this helpful
I use this product on areas affected by arthritis and gout for relief. It works wonderfully, increasing strength in my wrist and allowing me to lift items I previously struggled with. The smell isn’t great initially, but it dissipates quickly.
Read More
7.5
Large bath
Very good, a large bath that is excellent for treating arthritis, and it also serves as a hair conditioner.
Read More
Medical Researches
SCIENTIFIC SCORE
Moderately Effective
Based on 9 Researches
8.4
- All Researches
9
We explored the role of stromal cell-derived factor 1 (SDF-1) in alleviating osteoarthritis (OA), the most prevalent joint disease affecting millions. Our research delved into how SDF-1 could mitigate the progression of OA symptoms, focusing specifically on its impact on mitochondrial dysfunction within cartilage cells.
Using both OA chondrocytes and a collagen-induced osteoarthritis (CIOA) mouse model, we treated these cells and animals with SDF-1. We then assessed various markers related to mitochondrial function and cartilage health. Interestingly, we discovered that levels of important proteins like SOD2 and PGC-1α were lower in OA affected cells and tissues. Treatment with SDF-1 notably corrected these deficits, suggesting a promising pathway for restoring mitochondrial health and, consequently, improving OA symptoms.
Notably, when we inhibited Sirt3—an enzyme linked to mitochondrial function—prior to SDF-1 treatment, the benefits were diminished. This suggests that the Sirt3/PGC-1α signaling pathway is critical for the therapeutic effect of SDF-1 in OA. Thus, our findings indicate that SDF-1 stands out as a potential new treatment for OA, offering hope beyond traditional symptom management strategies.
Using both OA chondrocytes and a collagen-induced osteoarthritis (CIOA) mouse model, we treated these cells and animals with SDF-1. We then assessed various markers related to mitochondrial function and cartilage health. Interestingly, we discovered that levels of important proteins like SOD2 and PGC-1α were lower in OA affected cells and tissues. Treatment with SDF-1 notably corrected these deficits, suggesting a promising pathway for restoring mitochondrial health and, consequently, improving OA symptoms.
Notably, when we inhibited Sirt3—an enzyme linked to mitochondrial function—prior to SDF-1 treatment, the benefits were diminished. This suggests that the Sirt3/PGC-1α signaling pathway is critical for the therapeutic effect of SDF-1 in OA. Thus, our findings indicate that SDF-1 stands out as a potential new treatment for OA, offering hope beyond traditional symptom management strategies.
Read More
9
Hydrogen sulfide improves arthritis treatment
We explored the impact of hydrogen sulfide (HS) on rheumatoid arthritis (RA) through a specially designed delivery system. Our research focused on a new type of nanoparticle called NaHS@Cy5@MS@SP, which allows for a controlled and targeted release of HS directly to the affected synovium. This innovative approach aims to address the limitations of traditional HS treatments, like sodium hydrosulfide, known for their short effectiveness.
By targeting fibroblast-like synoviocytes (FLSs), which play a major role in the inflammation and proliferation associated with RA, we observed that our nanoparticles not only delivered HS more effectively but also encouraged the production of enzymes that help regulate inflammation. This response was a game-changer: we found that the upregulation of these enzymes led to a decrease in the harmful overactivity of FLSs.
In tests conducted on arthritic mice, NaHS@Cy5@MS@SP showed significant reductions in symptoms compared to free sodium hydrosulfide. Notably, it worked by inactivating the Hedgehog signaling pathway, a key contributor to RA’s progression. As a result, we noted improvements in joint health, including decreased synovial hyperplasia and less damage to bone and cartilage.
Overall, this study highlights a promising approach to managing RA through targeted delivery of HS, positioning NaHS@Cy5@MS@SP as a potential therapeutic strategy.
By targeting fibroblast-like synoviocytes (FLSs), which play a major role in the inflammation and proliferation associated with RA, we observed that our nanoparticles not only delivered HS more effectively but also encouraged the production of enzymes that help regulate inflammation. This response was a game-changer: we found that the upregulation of these enzymes led to a decrease in the harmful overactivity of FLSs.
In tests conducted on arthritic mice, NaHS@Cy5@MS@SP showed significant reductions in symptoms compared to free sodium hydrosulfide. Notably, it worked by inactivating the Hedgehog signaling pathway, a key contributor to RA’s progression. As a result, we noted improvements in joint health, including decreased synovial hyperplasia and less damage to bone and cartilage.
Overall, this study highlights a promising approach to managing RA through targeted delivery of HS, positioning NaHS@Cy5@MS@SP as a potential therapeutic strategy.
Read More
9
In our exploration of how certain natural compounds can impact rheumatoid arthritis (RA), we focused on the total flavonoids derived from Schltr., specifically identifying the effects of quercetin. Our research employed various methods, including cellular and animal models, to examine how these compounds inhibit TNF-α, a key player in inflammation and joint deterioration.
We discovered that quercetin stands out among several compounds, demonstrating a strong ability to reduce TNF-α activity. This reduction corresponds with decreased cellular injury and apoptosis in our models, showcasing quercetin's potential as a protective agent against RA symptoms. Through advanced techniques such as molecular docking and thermal profiling, we verified that quercetin binds to TNF-α, eventually diminishing the inflammatory processes related to arthritis.
The findings suggest that quercetin plays a significant role in suppressing the TNF-α/NF-κB signaling pathway, which is crucial in the development of RA. By blocking certain inflammatory responses, quercetin appears to mitigate pain and joint damage, positioning it as a hopeful candidate for RA treatment. Overall, our investigation highlights quercetin's promising properties as a natural anti-inflammatory agent for those suffering from arthritis.
We discovered that quercetin stands out among several compounds, demonstrating a strong ability to reduce TNF-α activity. This reduction corresponds with decreased cellular injury and apoptosis in our models, showcasing quercetin's potential as a protective agent against RA symptoms. Through advanced techniques such as molecular docking and thermal profiling, we verified that quercetin binds to TNF-α, eventually diminishing the inflammatory processes related to arthritis.
The findings suggest that quercetin plays a significant role in suppressing the TNF-α/NF-κB signaling pathway, which is crucial in the development of RA. By blocking certain inflammatory responses, quercetin appears to mitigate pain and joint damage, positioning it as a hopeful candidate for RA treatment. Overall, our investigation highlights quercetin's promising properties as a natural anti-inflammatory agent for those suffering from arthritis.
Read More
9
We set out to investigate whether proteins from the Clonorchis sinensis parasite could help reduce inflammation in rheumatoid arthritis (RA) and ankylosing spondylitis (AS). Our research involved analyzing blood samples from healthy individuals, as well as patients with these conditions, to assess how these proteins affected immune cells.
Through our experiments, we discovered that treatment with Clonorchis sinensis excretory/secretory proteins (CS-ESP) didn’t harm the health of the blood cells. In fact, these proteins significantly decreased the levels of certain inflammatory markers like IL-17A and GM-CSF that are associated with these types of arthritis.
We also tested these proteins in a mouse model of arthritis and found that CS-ESP notably alleviated symptoms like pain and swelling. Moreover, we isolated specific proteins, Cs-GT and Cs-Severin, which showed similar anti-inflammatory properties without affecting cell viability.
Overall, our findings suggest that these proteins may hold promise as new treatments to improve the signs and symptoms of arthritis. This study opens the door to further research on how such proteins can be used in therapeutic applications for arthritis patients.
Through our experiments, we discovered that treatment with Clonorchis sinensis excretory/secretory proteins (CS-ESP) didn’t harm the health of the blood cells. In fact, these proteins significantly decreased the levels of certain inflammatory markers like IL-17A and GM-CSF that are associated with these types of arthritis.
We also tested these proteins in a mouse model of arthritis and found that CS-ESP notably alleviated symptoms like pain and swelling. Moreover, we isolated specific proteins, Cs-GT and Cs-Severin, which showed similar anti-inflammatory properties without affecting cell viability.
Overall, our findings suggest that these proteins may hold promise as new treatments to improve the signs and symptoms of arthritis. This study opens the door to further research on how such proteins can be used in therapeutic applications for arthritis patients.
Read More
9
We examined how a biomimetic nanocarrier can enhance the delivery of chrysin, a natural compound known for its anti-inflammatory properties, specifically geared toward treating rheumatoid arthritis (RA). RA is characterized by chronic inflammation in the joints, leading to pain and disability.
In our approach, we utilized fibroblast-like synoviocyte (FLS) membrane proteins to create FMPlipo@C, a unique chrysin-loaded liposome. This method takes advantage of the natural affinity these proteins have for inflamed joints, effectively targeting the affected areas and facilitating the release of chrysin exactly where it's needed most.
Our findings showed that FMPlipo@C significantly reduced inflammation in collagen-induced rheumatoid arthritis model mice. It works by suppressing the HIF-1α/iNOS/NLRP3 pathway, which is crucial in the inflammatory response. By doing this, we observed that it not only protects the cartilage but also prevents bone erosion, leading to reduced swelling and stiffness in the joints.
This innovative strategy highlights the potential of targeting treatments more precisely, paving the way for improved therapeutic options for those struggling with rheumatoid arthritis.
In our approach, we utilized fibroblast-like synoviocyte (FLS) membrane proteins to create FMPlipo@C, a unique chrysin-loaded liposome. This method takes advantage of the natural affinity these proteins have for inflamed joints, effectively targeting the affected areas and facilitating the release of chrysin exactly where it's needed most.
Our findings showed that FMPlipo@C significantly reduced inflammation in collagen-induced rheumatoid arthritis model mice. It works by suppressing the HIF-1α/iNOS/NLRP3 pathway, which is crucial in the inflammatory response. By doing this, we observed that it not only protects the cartilage but also prevents bone erosion, leading to reduced swelling and stiffness in the joints.
This innovative strategy highlights the potential of targeting treatments more precisely, paving the way for improved therapeutic options for those struggling with rheumatoid arthritis.
Read More
User Reviews
USERS' SCORE
Good
Based on 3 Reviews
8.3
- All Reviews
- Positive Reviews
- Negative Reviews
9
Great help
Wonderful. Simply a great, pure product that we are using for arthritis, and it has proven to be very helpful for my husband's bad back. I love that it's entirely natural.
Read More
7.5
Strength and mobility
12 people found this helpful
I use this product on areas affected by arthritis and gout for relief. It works wonderfully, increasing strength in my wrist and allowing me to lift items I previously struggled with. The smell isn’t great initially, but it dissipates quickly.
Read More
7.5
Large bath
Very good, a large bath that is excellent for treating arthritis, and it also serves as a hair conditioner.
Read More
Frequently Asked Questions
9
Great help
Wonderful. Simply a great, pure product that we are using for arthritis, and it has proven to be very helpful for my husband's bad back. I love that it's entirely natural.
7.5
Large bath
Very good, a large bath that is excellent for treating arthritis, and it also serves as a hair conditioner.
8
Comparative effectiveness of IL-6 inhibitors
We aimed to explore the effectiveness of three different medications that target the interleukin-6 receptor (IL-6R) in treating rheumatoid arthritis (RA). These medications include subcutaneous sarilumab (SAR-SC), subcutaneous tocilizumab (TCZ-SC), and intravenous tocilizumab (TCZ-IV). Our study was designed as a multicenter cohort study, gathering data from patients in Japan over several years, focusing specifically on those who hadn’t previously received IL-6R inhibitors.
After treating patients for 24 weeks, we found that those taking SAR-SC experienced a statistically significant reduction in disease activity compared to those on TCZ-SC. This is exciting news for people with RA, as it suggests that SAR-SC could potentially offer better outcomes for initial treatment. However, when comparing TCZ-IV and TCZ-SC, we did not observe significant differences in effectiveness.
The findings underscore the importance of considering both the effectiveness and cost of treatment options. While SAR-SC seemed more effective, the pricing of medications, including TCZ-SC and its biosimilars, should be factored into treatment decisions. Overall, our research contributes valuable insights into how these protein treatments can influence the management of arthritis.
After treating patients for 24 weeks, we found that those taking SAR-SC experienced a statistically significant reduction in disease activity compared to those on TCZ-SC. This is exciting news for people with RA, as it suggests that SAR-SC could potentially offer better outcomes for initial treatment. However, when comparing TCZ-IV and TCZ-SC, we did not observe significant differences in effectiveness.
The findings underscore the importance of considering both the effectiveness and cost of treatment options. While SAR-SC seemed more effective, the pricing of medications, including TCZ-SC and its biosimilars, should be factored into treatment decisions. Overall, our research contributes valuable insights into how these protein treatments can influence the management of arthritis.
9
Hydrogen sulfide improves arthritis treatment
We explored the impact of hydrogen sulfide (HS) on rheumatoid arthritis (RA) through a specially designed delivery system. Our research focused on a new type of nanoparticle called NaHS@Cy5@MS@SP, which allows for a controlled and targeted release of HS directly to the affected synovium. This innovative approach aims to address the limitations of traditional HS treatments, like sodium hydrosulfide, known for their short effectiveness.
By targeting fibroblast-like synoviocytes (FLSs), which play a major role in the inflammation and proliferation associated with RA, we observed that our nanoparticles not only delivered HS more effectively but also encouraged the production of enzymes that help regulate inflammation. This response was a game-changer: we found that the upregulation of these enzymes led to a decrease in the harmful overactivity of FLSs.
In tests conducted on arthritic mice, NaHS@Cy5@MS@SP showed significant reductions in symptoms compared to free sodium hydrosulfide. Notably, it worked by inactivating the Hedgehog signaling pathway, a key contributor to RA’s progression. As a result, we noted improvements in joint health, including decreased synovial hyperplasia and less damage to bone and cartilage.
Overall, this study highlights a promising approach to managing RA through targeted delivery of HS, positioning NaHS@Cy5@MS@SP as a potential therapeutic strategy.
By targeting fibroblast-like synoviocytes (FLSs), which play a major role in the inflammation and proliferation associated with RA, we observed that our nanoparticles not only delivered HS more effectively but also encouraged the production of enzymes that help regulate inflammation. This response was a game-changer: we found that the upregulation of these enzymes led to a decrease in the harmful overactivity of FLSs.
In tests conducted on arthritic mice, NaHS@Cy5@MS@SP showed significant reductions in symptoms compared to free sodium hydrosulfide. Notably, it worked by inactivating the Hedgehog signaling pathway, a key contributor to RA’s progression. As a result, we noted improvements in joint health, including decreased synovial hyperplasia and less damage to bone and cartilage.
Overall, this study highlights a promising approach to managing RA through targeted delivery of HS, positioning NaHS@Cy5@MS@SP as a potential therapeutic strategy.
9
In our exploration of how certain natural compounds can impact rheumatoid arthritis (RA), we focused on the total flavonoids derived from Schltr., specifically identifying the effects of quercetin. Our research employed various methods, including cellular and animal models, to examine how these compounds inhibit TNF-α, a key player in inflammation and joint deterioration.
We discovered that quercetin stands out among several compounds, demonstrating a strong ability to reduce TNF-α activity. This reduction corresponds with decreased cellular injury and apoptosis in our models, showcasing quercetin's potential as a protective agent against RA symptoms. Through advanced techniques such as molecular docking and thermal profiling, we verified that quercetin binds to TNF-α, eventually diminishing the inflammatory processes related to arthritis.
The findings suggest that quercetin plays a significant role in suppressing the TNF-α/NF-κB signaling pathway, which is crucial in the development of RA. By blocking certain inflammatory responses, quercetin appears to mitigate pain and joint damage, positioning it as a hopeful candidate for RA treatment. Overall, our investigation highlights quercetin's promising properties as a natural anti-inflammatory agent for those suffering from arthritis.
We discovered that quercetin stands out among several compounds, demonstrating a strong ability to reduce TNF-α activity. This reduction corresponds with decreased cellular injury and apoptosis in our models, showcasing quercetin's potential as a protective agent against RA symptoms. Through advanced techniques such as molecular docking and thermal profiling, we verified that quercetin binds to TNF-α, eventually diminishing the inflammatory processes related to arthritis.
The findings suggest that quercetin plays a significant role in suppressing the TNF-α/NF-κB signaling pathway, which is crucial in the development of RA. By blocking certain inflammatory responses, quercetin appears to mitigate pain and joint damage, positioning it as a hopeful candidate for RA treatment. Overall, our investigation highlights quercetin's promising properties as a natural anti-inflammatory agent for those suffering from arthritis.
9
We explored the role of stromal cell-derived factor 1 (SDF-1) in alleviating osteoarthritis (OA), the most prevalent joint disease affecting millions. Our research delved into how SDF-1 could mitigate the progression of OA symptoms, focusing specifically on its impact on mitochondrial dysfunction within cartilage cells.
Using both OA chondrocytes and a collagen-induced osteoarthritis (CIOA) mouse model, we treated these cells and animals with SDF-1. We then assessed various markers related to mitochondrial function and cartilage health. Interestingly, we discovered that levels of important proteins like SOD2 and PGC-1α were lower in OA affected cells and tissues. Treatment with SDF-1 notably corrected these deficits, suggesting a promising pathway for restoring mitochondrial health and, consequently, improving OA symptoms.
Notably, when we inhibited Sirt3—an enzyme linked to mitochondrial function—prior to SDF-1 treatment, the benefits were diminished. This suggests that the Sirt3/PGC-1α signaling pathway is critical for the therapeutic effect of SDF-1 in OA. Thus, our findings indicate that SDF-1 stands out as a potential new treatment for OA, offering hope beyond traditional symptom management strategies.
Using both OA chondrocytes and a collagen-induced osteoarthritis (CIOA) mouse model, we treated these cells and animals with SDF-1. We then assessed various markers related to mitochondrial function and cartilage health. Interestingly, we discovered that levels of important proteins like SOD2 and PGC-1α were lower in OA affected cells and tissues. Treatment with SDF-1 notably corrected these deficits, suggesting a promising pathway for restoring mitochondrial health and, consequently, improving OA symptoms.
Notably, when we inhibited Sirt3—an enzyme linked to mitochondrial function—prior to SDF-1 treatment, the benefits were diminished. This suggests that the Sirt3/PGC-1α signaling pathway is critical for the therapeutic effect of SDF-1 in OA. Thus, our findings indicate that SDF-1 stands out as a potential new treatment for OA, offering hope beyond traditional symptom management strategies.
References
- Onishi A, Tanaka M, Fujii T, Murata K, Murakami K, et al. Comparative effectiveness of subcutaneous sarilumab 200 mg biweekly, subcutaneous Tocilizumab 162 mg biweekly, and intravenous Tocilizumab 8 mg/kg every 4 weeks in patients with rheumatoid arthritis: a prospective cohort study. Arthritis Res Ther. 2025;27:52. 10.1186/s13075-025-03514-x
- Zhao Y, Lin D, Zhu X, Yan J, Liang Y, et al. SDF-1 alleviates osteoarthritis by resolving mitochondrial dysfunction through the activation of the Sirt3/PGC-1α signalling pathway. Arthritis Res Ther. 2025;27:51. 10.1186/s13075-025-03509-8
- Zhu XX, Xu AJ, Cai WW, Han ZJ, Zhang SJ, et al. NaHS@Cy5@MS@SP nanoparticles improve rheumatoid arthritis by inactivating the Hedgehog signaling pathway through sustained and targeted release of HS into the synovium. J Nanobiotechnology. 2025;23:192. 10.1186/s12951-025-03286-1
- Chen S, Xue W, Wu Z, Lu D, Zheng L, et al. Quercetin, a Compound of the Total Flavonoids of Schltr., Ameliorates Rheumatoid Arthritis by Targeting TNF-α. J Inflamm Res. 2025;18:2879. 10.2147/JIR.S497166
- Stöckl S, Taheri S, Maier V, Asid A, Toelge M, et al. Effects of intra-articular applied rat BMSCs expressing alpha-calcitonin gene-related peptide or substance P on osteoarthritis pathogenesis in a murine surgical osteoarthritis model. Stem Cell Res Ther. 2025;16:117. 10.1186/s13287-025-04155-2
- Weinblatt ME, Taylor PC, McInnes IB, Atsumi T, Strand V, et al. Long-term safety and efficacy of anti-GM-CSF otilimab in patients with rheumatoid arthritis: long-term extension of three phase 3 randomised trials (contRAst X). BMJ Open. 2025;15:e088869. 10.1136/bmjopen-2024-088869
- Kim MJ, Yoo HM, Lee YJ, Jang HH, Shim SC, et al. Clonorchis sinensis excretory/secretory proteins ameliorate inflammation in rheumatoid arthritis and ankylosing spondylitis. Parasit Vectors. 2025;18:85. 10.1186/s13071-025-06677-3
- Liu L, Ambe K, Onishi M, Yoshii Y, Makino T, et al. Comparison of the Efficacy and Safety of Disease-Modifying Antirheumatic Drugs Combination Therapies: A Systematic Review and Network Meta-Analysis. Clin Transl Sci. 2025;18:e70156. 10.1111/cts.70156
- Chen M, Wang Z, Chen H, Li J, Guo X, et al. Biomimetic Nanoparticles Inhibit the HIF-1α/iNOS/NLRP3 Pathway to Alleviate Rheumatoid Arthritis. Nano Lett. 2025. 10.1021/acs.nanolett.4c05782
